A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.
Endocrine therapy (ET) is one of the main systemic treatments for patients with breast cancer. To our knowledge, few studies have addressed the performance of ET or relevant influencing factors in cancer treatment in China. By retrospectively analyzing the clinicopathological data on breast cancer c...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/037d5f8c30b548a3845f282fe4ec9339 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:037d5f8c30b548a3845f282fe4ec9339 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:037d5f8c30b548a3845f282fe4ec93392021-11-25T06:07:59ZA nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.1932-620310.1371/journal.pone.0100159https://doaj.org/article/037d5f8c30b548a3845f282fe4ec93392014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25036532/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Endocrine therapy (ET) is one of the main systemic treatments for patients with breast cancer. To our knowledge, few studies have addressed the performance of ET or relevant influencing factors in cancer treatment in China. By retrospectively analyzing the clinicopathological data on breast cancer collected from representative hospitals of 7 traditional areas in China in one random month from each year between year 1999 and 2008, we found that: 1) The rate of the use of hormone receptor (HR) testing was 83.8% (3529/4211), with the estrogen receptor-positive (ER+) rate and/or the progesterone receptor-positive (PR+) rate being 67.9% (2395/3529), and the ER-PR rate being 32.1% (1134/3529). 2) Of the 1599 patients who had received ET, 999 patients (58.3%) were premenopausal while 600 (41.7%) were postmenopausal; 1598 patients received adjuvant hormonal therapy (AHT), whereas only 1 patient received palliative therapy. The medications mainly administered to patients were anti-estrogen agents (80.3% [1283/1598]), followed by AIs (15.5% [248/1598]). Of the 1598 patients receiving AHT, 1416 patients (88.6%) were positive for ER and/or PR, while 75 (4.7%) were negative for both and 108 patients (6.7%) had unknown HR status. The ratio of the use of endocrine therapy for breast cancer patients with ER+ and/or PR+ status was 60.0% (1416/2395). 3) Results from the logistic regression analysis revealed that geography, occupations, and history of chemotherapy and surgery were dependent factors affecting the application of ET in breast cancer treatment in China (P<0.001). In conclusion, the use of ET on Chinese women with breast cancer is increasingly and gradually accounted into the standardized process. Economic status, occupations, and history of chemotherapy and surgery were key factors affecting the application of ET. People residing in developed areas, engaging in mental labour, having history of chemotherapy and surgery are susceptible to accept ET.Can ZhouJian jun HeJing LiJin hu FanBin ZhangHong jian YangXiao ming XieZhong hua TangHui LiJia yuan LiShu lian WangYou lin QiaoRong HuangPin ZhangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e100159 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Can Zhou Jian jun He Jing Li Jin hu Fan Bin Zhang Hong jian Yang Xiao ming Xie Zhong hua Tang Hui Li Jia yuan Li Shu lian Wang You lin Qiao Rong Huang Pin Zhang A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| description |
Endocrine therapy (ET) is one of the main systemic treatments for patients with breast cancer. To our knowledge, few studies have addressed the performance of ET or relevant influencing factors in cancer treatment in China. By retrospectively analyzing the clinicopathological data on breast cancer collected from representative hospitals of 7 traditional areas in China in one random month from each year between year 1999 and 2008, we found that: 1) The rate of the use of hormone receptor (HR) testing was 83.8% (3529/4211), with the estrogen receptor-positive (ER+) rate and/or the progesterone receptor-positive (PR+) rate being 67.9% (2395/3529), and the ER-PR rate being 32.1% (1134/3529). 2) Of the 1599 patients who had received ET, 999 patients (58.3%) were premenopausal while 600 (41.7%) were postmenopausal; 1598 patients received adjuvant hormonal therapy (AHT), whereas only 1 patient received palliative therapy. The medications mainly administered to patients were anti-estrogen agents (80.3% [1283/1598]), followed by AIs (15.5% [248/1598]). Of the 1598 patients receiving AHT, 1416 patients (88.6%) were positive for ER and/or PR, while 75 (4.7%) were negative for both and 108 patients (6.7%) had unknown HR status. The ratio of the use of endocrine therapy for breast cancer patients with ER+ and/or PR+ status was 60.0% (1416/2395). 3) Results from the logistic regression analysis revealed that geography, occupations, and history of chemotherapy and surgery were dependent factors affecting the application of ET in breast cancer treatment in China (P<0.001). In conclusion, the use of ET on Chinese women with breast cancer is increasingly and gradually accounted into the standardized process. Economic status, occupations, and history of chemotherapy and surgery were key factors affecting the application of ET. People residing in developed areas, engaging in mental labour, having history of chemotherapy and surgery are susceptible to accept ET. |
| format |
article |
| author |
Can Zhou Jian jun He Jing Li Jin hu Fan Bin Zhang Hong jian Yang Xiao ming Xie Zhong hua Tang Hui Li Jia yuan Li Shu lian Wang You lin Qiao Rong Huang Pin Zhang |
| author_facet |
Can Zhou Jian jun He Jing Li Jin hu Fan Bin Zhang Hong jian Yang Xiao ming Xie Zhong hua Tang Hui Li Jia yuan Li Shu lian Wang You lin Qiao Rong Huang Pin Zhang |
| author_sort |
Can Zhou |
| title |
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| title_short |
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| title_full |
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| title_fullStr |
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| title_full_unstemmed |
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. |
| title_sort |
nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for chinese females with breast cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/037d5f8c30b548a3845f282fe4ec9339 |
| work_keys_str_mv |
AT canzhou anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jianjunhe anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jingli anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jinhufan anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT binzhang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT hongjianyang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT xiaomingxie anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT zhonghuatang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT huili anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jiayuanli anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT shulianwang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT youlinqiao anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT ronghuang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT pinzhang anationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT canzhou nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jianjunhe nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jingli nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jinhufan nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT binzhang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT hongjianyang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT xiaomingxie nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT zhonghuatang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT huili nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT jiayuanli nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT shulianwang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT youlinqiao nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT ronghuang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer AT pinzhang nationwidemulticenter10year19992008retrospectiveclinicalstudyofendocrinetherapyforchinesefemaleswithbreastcancer |
| _version_ |
1718414144101679104 |